Business Wire

MA-VERACODE

Share
Healthcare Sector Leads the Way for Fix Rate of Software Security Flaws

Veracode, a leading global provider of application security testing solutions, today revealed that the healthcare sector takes first place for the proportion of software security flaws that are fixed, at 27 percent. The sector overtook financial services as the top-performing industry, demonstrating healthcare providers have made good headway toward the goal of making their software more secure over the past year.

The data was published in the company’s annual State of Software Security (SoSS) report v12, which analyzed 20 million scans across half a million applications in the healthcare, financial, technology, manufacturing, retail, and government sectors.

Chris Eng, Chief Research Officer at Veracode, said, “Healthcare is one of the more highly regulated sectors and is considered critical infrastructure by the government, so it’s encouraging to see the sector performs comparatively well in terms of overall flaw remediation. We hope healthcare developers and IT staff see this as a welcome ray of sunshine amidst the all-too-often gloomy realm of software security. There is still work to do, so here’s to more improvements in the years to come.”

Despite taking the top spot for fix rate, 77 percent of applications in the healthcare industry contain vulnerabilities, with 21 percent of applications containing high severity vulnerabilities. The sector also has ample room for improvement in terms of the time spent to fix flaws once they’re detected, taking up to a whopping 447 days to reach the halfway point of remediation.

Healthcare Breach Costs Are the Most Expensive

With healthcare companies incurring the highest average breach costs, at a new record high of $10.1 million*, taking proactive steps to minimize the risk of a cyberattack is imperative. Since data breaches in highly regulated industries tend to be associated with larger long-term costs that accrue over the ensuing years, the industry would benefit from even greater comprehensive efforts to address security earlier in the software development lifecycle.

Of the six industries analyzed, healthcare providers rank toward the bottom for the proportion of applications with any flaws, and second to last for the percentage of high-severity flaws—defined as those that present a serious risk to the application and organization if they were to be exploited. When it comes to the types of flaws discovered from dynamic analysis of applications in the sector, compared to other industries healthcare providers perform well for authentication issues and insecure dependencies, but have a higher incidence of cryptographic and deployment configuration issues.

Eng said, “We know that no application will ever be 100 percent free of security flaws, so it’s important that businesses take all necessary steps to minimize risk as much as possible. This includes scanning at a regular, rapid pace using multiple testing types, integrating testing tools into developer environments, and providing hands-on training to help developers understand the origin of flaws and how to fix or prevent them entirely. The healthcare sector should also take extra care to prioritize critical flaws—those vulnerabilities that could have a catastrophic impact if left unaddressed for too long.”

Andrew McCall, Vice President of Engineering, Azalea Health Innovations, said, “The biggest obstacle to building security into our workflows is that developers will treat security as just a checkbox. But security is an ongoing process and has to be top of mind throughout the software development life cycle. We chose Veracode because it was the easiest and best solution when it comes to integrating into our existing processes.”

Third-party Library Security

Considering a sharp increase in regulations to secure the software supply chain over the past year, the report analyzed third-party libraries to identify how vulnerabilities discovered through software composition analysis (SCA) behave. Overall, around 30 percent of vulnerable libraries remain unresolved after two years; however, that statistic reduces to 25 percent for the healthcare sector. In fact, while the overall ratio of vulnerable libraries found by SCA trends down steadily over time, healthcare experienced a brief upward spike before driving rates down dramatically over the last year or so.

The Veracode State of Software Security v12 healthcare snapshot is available to download here and the full report is available here.

* IBM Security and The Ponemon Institute, “Cost of a Data Breach Report 2022”: https://www.ibm.com/downloads/cas/3R8N1DZJ, July 2022

About the State of Software Security Report

The Veracode State of Software Security (SoSS) v12 analyzed the full historical data from Veracode services and customers. This accounts for a total of more than half a million applications (592,720) that used all scan types, more than a million dynamic analysis scans (1,034,855), more than five million static analysis scans (5,137,882) and more than 18 million software composition analysis scans (18,473,203). All those scans produced 42 million raw static findings, 3.5 million raw dynamic findings, and six million raw SCA findings.

The data represents large and small companies, commercial software suppliers, software outsourcers, and open-source projects. In most analyses, an application was counted only once, even if it was submitted multiple times as vulnerabilities were remediated, and new versions uploaded.

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.

Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005100/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye